IGF1R and prostate cancer: This data is consistent with the finding that suppression of IRS-1 inhibits the growth of BRCA1-deficient tumor cells [47], and that HR deficient prostate cancer cells (mutated/methylated BRCA1) are more sensitive to IGF-1R inhibition [48].